11.31
+0.22(+1.98%)
Currency In USD
Address
480 Pleasant Street
Watertown, MA 02472
United States of America
Phone
617 926 5000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
165
First IPO Date
January 27, 2005
| Name | Title | Pay | Year Born |
| Dr. Anna Kluczewska | Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd | 164,457 | N/A |
| Dr. Jay S. Duker M.D. | President, Chief Executive Officer & Director | 1.19M | 1959 |
| Mr. David Scott Jones M.A. | Senior Vice President & Chief Commercial Officer | 672,084 | 1967 |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer | 742,578 | 1983 |
| Mr. George O. Elston CPA | Executive Vice President & Chief Financial Officer | 824,474 | 1965 |
| Ms. Jennifer Leonard | Chief People Officer & Senior Vice President of IT | 0 | N/A |
| Dr. Marcia Sellos-Moura Ph.D. | Senior Vice President and Head of Development & Program Management | 0 | N/A |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer | 0 | N/A |
| Mr. Michael J. Maciocio | Chief Manufacturing Officer | 0 | N/A |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Secretary | 0 | N/A |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.